Clinical Labs of Hawaii provides test updates for educational purposes to physicians, specialists, and the general public.
On August 3, 2020 Clinical Labs of Hawaii will begin offering nasal (anterior nares) collection of SARS-CoV-2 specimens at select locations.
On June 4, 2020, the U.S. Department of Health and Human Services (HHS) published new requirements for patient data collection and reporting for COVID-19 test results. Please review this bulletin for more details.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) molecular testing specimen types.
On May 19, 2020, Clinical Laboratories of Hawaii (CLH) began testing for SARS-CoV-2, the virus that causes COVID-19, using a new high-throughput system, called the Aptima® SARS-CoV-2 Assay conducted on the Hologic Panther instrument.
Please review guidelines from the federal government’s COVID-19 Uninsured Program.
Please review the Clinical Labs of Hawaii frequently asked questions for answers regarding SARS-CoV-2 (COVID-19) serology testing.
Effective April 30, 2020, Clinical Labs of Hawaii began offering serology testing for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).
Beginning March 1, 2020, United Healthcare Insurance will require prior authorization/notification for genetic and molecular testing performed in an outpatient setting.
CLH offers the FilmArray Respiratory Panel from BioFire Diagnostics for the detection of 17 respiratory viruses and 3 bacteria from a single specimen. This panel does NOT test for the SARS-CoV-2 virus.
Biotin administration (especially in high doses) may impact common, immunoassay-based, laboratory tests.
CLH/PPPL will be performing Human Papillomavirus (HPV) testing locally on Oahu using the Aptima nucleic acid amplification assay.